Navigation Links
Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
Date:10/31/2011

BLUE BELL, Pa., Oct. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon® vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines (see VGX-3100 – Cervical cancer). Inovio is currently enrolling patients with CIN 2/3 or CIN 3 cervical dysplasias in its Phase II clinical study being conducted in multiple centers around the US and sites in Canada, Korea, South Africa and Australia.

The article noted: "Fierce Vaccines spotlights 10 therapeutic vaccines now being tested in humans and generating buzz. Those for cancer get the most attention, in part because their anticipated gentleness stands in such stark contrast to the known toxicities of conventional chemotherapies….

"[Inovio's] VGX-3100 is a therapeutic DNA vaccine candidate, now in Phase II testing for the treatment of cervical dysplasia and cancer caused by human papillomavirus (HPV) types 16 and 18. These sexually transmitted strains are thought to cause up to 70% of cervical cancer cases. Inovio is conducting Phase II clinical trials of related vaccine candidates based on DNA associated with leukemia and hepatitis C virus, and Phase I studies for influenza and HIV. The company's vaccine candidates are similar to gene therapy, in that they are designed to insert into patients' cells a piece of DNA coding for an antigenic protein related to a particular disease. In theory, if enough DNA can get into cells even temporarily, those cells will prod
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 New-generation electronic ... highly portable and lightweight. Simultaneously, circuitry is increasing ... processing speed to which it performs at. Connecting ... electronics and military equipment, such as cameras or ... micro-circular and nano-circular connectors include custom cable designs ...
(Date:6/18/2013)... , June 18, 2013 Apama ... on the development of next-generation atrial fibrillation technologies, ... 8295902 by the US Patent and Trademark Office ... low profile electrode assemblies for use on expandable ... or other surgical procedures. "We are ...
(Date:6/17/2013)... , June 17, 2013 Vanda Pharmaceuticals ... additional data today at ENDO 2013, the Endocrine ... tasimelteon can entrain (synchronize) both melatonin and cortisol ... reset the master body clock and address the ... (Non-24).  The SET (Safety and Efficacy of Tasimelteon) ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
... China, April 19, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese medicines ("TCM") in China, today announced that ... owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd ("Renhuang"), ...
... Henry Schein, Inc. (Nasdaq: HSIC ), the largest ... announced today that it will release its first quarter 2011 ... 3, 2011, and will provide a live webcast of its ... a.m. Eastern Daylight Time. Speakers on the call will include ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT 2
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
(Date:6/18/2013)... More than 1.1 million people in the ... to the Centers for Disease Control and Prevention (CDC). Of ... support of National HIV Testing Day on June 27, Allsup, ... (SSDI) representation, the CDC and other organizations are raising awareness ... reports about 50,000 new HIV infections each year. Along with ...
(Date:6/18/2013)... June 18, 2013 The Elizabeth Glaser ... State and the U.S. President’s Emergency Plan for AIDS ... celebrate significant new milestones in the global effort to ... Kerry announced that as of June 2013, one million ... support. Since PEPFAR’s inception in 2003, EGPAF has ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Two months ago, ... going into surgery for a second session of a silicone ... Miami-Dade County. The treatment was allegedly performed by a mystery ... the board. According to Dr. Bernabe Vazquez of ... receiving such treatments from doctor’s who are not board certified ...
(Date:6/18/2013)... A new $119 million industry is taking the ... redefining the way consumers get their seafood. , ... chefs on the Emerald Coast panhandle of Northwest Florida ... the promising industry of aquaculture. , The word “sustainable” ... to fully partake in the effort, especially when it ...
Breaking Medicine News(10 mins):Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:New $119 Million Industry Swimming Up the East Coast 2
... Ohio Warm, cooperative co-parenting between mothers and fathers ... some types of behavior problems, a new study suggests. ... have difficulty regulating their behavior and attention levels ... at changes in children,s level of aggressive behavior and ...
... Jacobi, Ph.D., an environmental analyst for Lincoln Park Zoo,s ... of highly qualified candidates worldwide to receive the prestigious ... the Cedar Tree Foundation. It is recognized as the ... , The fellowship program is aimed at finding solutions ...
... Computer, www.CardioCareLive.com takes place entirely online Tuesday March 3 and ... MD, the real physician behind the movie starring Robin Williams, is ... , ... Needham, MA (PRWEB) March 3, 2009 -- ...
... heel ulcers to zero, saves nearly $2 millionCARY, Ill., ... are sedated or immobilized are at a higher risk ... flexion contractures, conditions that can significantly reduce quality of ... the use of heel protectors resulted in 100 percent ...
... Patient Advocates and Broader Kidney Care Community,in partnership with ... March 3 Kidney Care Partners (KCP) - ... providers and manufacturers working together to improve quality of ... - today expressed alarm regarding the racial ...
... patients now have access to second-generation drug-eluting stentNATICK, ... BSX ) today announced the launch ... in Japan. The product was approved on ... and Welfare, and reimbursement was granted yesterday by ...
Cached Medicine News:Health News:Supportive co-parenting may reduce some child behavior problems 2Health News:Supportive co-parenting may reduce some child behavior problems 3Health News:Lincoln Park Zoo researcher awarded prestigious conservation biology fellowship 2Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:Clinical Intervention Eliminates Heel Ulcer Incidents in ICU 2Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 2Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 3Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3
... The ACS:180 SE is ... ACS:180 PLUS, consisting of important ... further simplify routine operation and ... represents the "Next Generation" ACS:180. ...
... Chrono-log's wide range of Platelet aggregometers ... to meet particular needs. Single, dual ... with chart recorder outputs or digital ... Chrono-log Optical aggregometers, which measure platelet ...
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
... The PAP-4 is a four channel Platelet ... available: von willebrand assay (Ristocetin cofactor), platelet ... also be used for the evaluation and ... channels allow four tests to be run ...
Medicine Products: